 Home > Biochemistry News > Biotechnology News > Bristol-Myers Squibb S1P receptor modulator gains new indications for the treatment of ulcerative colitis

Bristol-Myers Squibb S1P receptor modulator gains new indications for the treatment of ulcerative colitis

 Last Update: 2021-06-05
 Source: Internet
 Author: User

Tags

chronic granulomatous disease

key life

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Bristol-Myers Squibb (BMS) today announced that the US FDA has approved Zeposia (ozanimod) 0.

This approval is based on the results of a pivotal Phase 3 clinical trial called True North.

Ulcerative colitis is a chronic inflammatory bowel disease (IBD), which is characterized by a long-term abnormal immune response that leads to persistent inflammation and ulcers in the mucous membrane of the colon or rectum.

Zeposia (ozanimod) is an oral S1P receptor modulator that binds to S1P receptors 1 and 5 with high affinity.

Note: The original text has been deleted

Reference materials:

[1] US Food and Drug Administration Approves Bristol Myers Squibb's Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express | Treatment of ulcerative colitis, Bristol-Myers Squibb S1P receptor modulator gains new indications

06-01

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Bristol-Myers Squibb S1P receptor modulator gains new indications for the treatment of ulcerative colitis

Related Articles

Express | Treatment of ulcerative colitis, Bristol-Myers Squibb S1P receptor modulator gains new indications